APGE insider files to sell 22,000 shares

APGE reported an intended sale of 22,000 common shares under Rule 144, comprised of 16,500 shares from exercised stock options and 5,500 shares from restricted stock awards.

Rhea-AI Filing Summary

APGE reported an intended sale of 22,000 common shares under Rule 144, comprised of 16,500 shares from exercised stock options and 5,500 shares from restricted stock awards.

The filing also discloses two 10b5-1 sales in the past three months totaling 11,000 shares (5,500 on 2026-04-01 for $466,639.80 and 5,500 on 2026-03-04 for $390,839.05).

Insights

Equity Compliance Officer

Rule 144 notice lists 22,000 shares for sale, including option exercises and RSAs.

The filing documents an intent to sell 22,000 common shares, split between 16,500 from option exercise and 5,500 restricted stock awards, which matches the top-line quantity shown.

Cash‑flow treatment and timing beyond the dates shown are not specified in the excerpt; past 10b5-1 executions on 2026-03-04 and 2026-04-01 are recorded with exact proceeds.

Key Figures

Shares to be sold: 22,000 shares Option-derived shares: 16,500 shares Restricted Stock Awards: 5,500 shares +3 more

6 metrics

Shares to be sold 22,000 shares Rule 144 notice (total shown at top of excerpt)

Option-derived shares 16,500 shares Exercise of Stock Options dated <date>2026-05-06</date>

Restricted Stock Awards 5,500 shares Restricted Stock Awards dated <date>2022-12-14</date>

10b5-1 sale on 2026-04-01 5,500 shares Proceeds <money>$466,639.80</money>

10b5-1 sale on 2026-03-04 5,500 shares Proceeds <money>$390,839.05</money>

Total recent 10b5-1 sales 11,000 shares Two sales in past three months (March and April 2026)

Key Terms

Rule 144, 10b5-1, Restricted Stock Awards

3 terms

Rule 144 regulatory

"intended sale of 22,000 common shares under Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for CARL DAMBKOWSKI ... 5,500 ... 466639.80"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Restricted Stock Awards financial

"Restricted Stock Awards | Issuer | | | 5500 | 12/14/2022"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does APGE's Form 144 disclose about shares to be sold?

It discloses an intended sale of 22,000 common shares composed of 16,500 from option exercise and 5,500 from restricted stock awards. The filing lists the source of each block and the dates tied to those securities.

How many APGE shares were sold recently under a 10b5-1 plan?

The filing reports two recent 10b5-1 sales totaling 11,000 shares: 5,500 sold on 2026-03-04 for $390,839.05 and 5,500 on 2026-04-01 for $466,639.80. These amounts are shown verbatim.

What portion of the 22,000 shares comes from exercised options for APGE?

The filing shows 16,500 shares tied to the exercise of stock options, representing the majority of the 22,000 shares the filer intends to sell. The exercise date listed is 2026-05-06 in the excerpt.

Do the Form 144 entries state who receives the sale proceeds?

The excerpt does not assign proceeds beyond listing sale amounts for past 10b5-1 transactions; it records transaction proceeds as $390,839.05 and $466,639.80 for the two executed sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:25 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001983476
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Apogee Therapeutics, Inc.
SEC File Number	001-41740
Address of Issuer	221 Crescent St., Building 17 Suite 102b Waltham MASSACHUSETTS 02453
Phone	6503945230
Name of Person for Whose Account the Securities are To Be Sold	CARL DAMBKOWSKI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	22000	1832380.00	69485247	05/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/06/2026	Exercise of Stock Options	Issuer			16500	05/06/2026	Cash
Common	12/14/2022	Restricted Stock Awards	Issuer			5500	12/14/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St., Building 17 Suite 102b Waltham MA 02453	Common	04/01/2026	5500	466639.80
10b5-1 Sales for CARL DAMBKOWSKI 221 Crescent St., Building 17 Suite 102b Waltham MA 02453	Common	03/04/2026	5500	390839.05

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	05/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/22/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Carl Dambkowski
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)